The Emerging Role of Novel Heterocyclic Derivatives in Cancer Therapy

Abstract

Cancer remains to pose a major worldwide health challenge because of its high incidence, complex pathophysiology, and poor prognosis in advanced stages. Conventional therapies, including chemotherapy, radiotherapy, immunotherapy, and hormonal treatments, have improved survival but are often accompanied by significant systemic toxicity, multidrug resistance, and low target selectivity. Heterocyclic compounds have emerged as pivotal scaffolds in anticancer drug discovery due to their structural diversity, capacity for functional modifications, and favorable pharmacokinetic and pharmacodynamic profiles. This review highlights recent advances in heterocyclic derivatives, including thiazolidine dione, 1,3,4-thiadiazole, and styryl-heterocyclic hybrids, emphasizing their mechanisms of action, structure–activity relationships, and clinical relevance. In addition, the review discusses the pharmacological potential of marketed heterocyclic anticancer drugs and provides insight into future directions for rational design, optimization, and targeted therapy development.